FIELD: medicine.
SUBSTANCE: reservatrol efficacy is studied in female Wistar rats with simulated osteoporosis by bilateral ovariectomy. For osteoporosis correction, reservatrol is administered in animal intraperitoneally for eight weeks after ovariectomy daily once a day in single dose 2 mg/kg. Osteoprotective action of reservatrol is estimated by a bone tissue microcirculation level and width of trabeculas of bone.
EFFECT: improved blood circulation and microarchitectonics of bone tissue in hypoestrogenic condition.
1 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR RESERVATROL AND ENALAPRIL BASED OSTEOPOROSIS CORRECTION AND FRAGILITY FRACTURE PREVENTION | 2010 |
|
RU2437160C1 |
METHOD FOR THE CORRECTION OF OSTEOPOROSIS AND OSTEOPOROTIC FRACTURES WITH 3-HYDROXY-2-ETHYL-6-METHYLPYRIDINIUM NICOTINATE IN EXPERIMENT | 2021 |
|
RU2763011C1 |
METHOD FOR CORRECTING OSTEOPOROSIS AND OSTEOPOROTIC FRACTURES WITH 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINIUM HYDROXYBUTANEDIOATE IN EXPERIMENT | 2021 |
|
RU2775439C1 |
METHOD OF OSTEOPOROSIS CORRECTION AND PREVENTION OF OSTEOPOROTIC FRACTURE BY MEANS OF ENALAPRILS | 2008 |
|
RU2369390C1 |
METHOD OF OSTEOPOROSIS CORRECTION AND PREVENTION OF OSTEOPOROTIC FRACTURES BY MEANS OF LOSARTAN | 2008 |
|
RU2369391C1 |
METHOD FOR CORRECTING BONE MICROCIRCULATION ACCOMPANYING EXPERIMENTALOSTEOPOROSIS AND UNDERLYING FRACTURES WITH USE OF COMBINATION OF L-ARGININE AND ENALAPRIL | 2013 |
|
RU2542424C1 |
METHOD OF CORRECTING MICROCIRCULATION IN BONE TISSUE WITH COMBINATION OF L-NORVALIN AND ROSUVASTATIN IN CASE OF EXPERIMENTAL OSTEOPOROSIS AND FRACTURES AT ITS BACKGROUND | 2013 |
|
RU2540927C1 |
METHOD FOR CORRECTING BONE MICROCIRCULATION ACCOMPANYING OSTEOPOROSIS AND UNDERLYING FRACTURES WITH USE OF COMBINATION OF L-ARGININE AND LOSARTAN | 2013 |
|
RU2542425C1 |
METHOD FOR CORRECTION OF BONE TISSUE MICROCIRCULATON IN EXPERIMENTAL OSTEOPOROSIS AND ASSOCIATED FRACTURES WITH COMBINATION OF RECOMBINANT ERYTHROPOIETIN AND ROSUVASTATIN | 2013 |
|
RU2541184C1 |
PHARMACOLOGICAL COMPOUND BASED ON 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINIUM N-ACETYL-6-AMINOHEXANOATE AND 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINIUM 3-PYRIDINOCARBONOATE AND ITS USE FOR CORRECTION AND PREVENTION OF OSTEOPOROSIS | 2023 |
|
RU2806116C1 |
Authors
Dates
2011-12-20—Published
2010-04-12—Filed